March 11, 2022 - … new Alzheimer’s disease research, as well as data for ADUHELM ® (aducanumab-avwa) injection 100 mg/mL for … on March 16, will include an examination of the ability of ADUHELM to reduce amyloid beta plaque and plasma p-tau181, … endpoints during the long-term extension phase of the ADUHELM clinical program. An oral presentation on March 18, …